Resmed (RSMDF) Notes Payables (2015 - 2026)

Resmed (RSMDF) has reported Notes Payables for 12 consecutive years, with $260.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Notes Payables rose 2525.76% year-over-year to $260.0 million; the trailing twelve-month figure through Jun 2026 stood at $260.0 million (up 2525.76% YoY), and the FY2026 full-year result was $260.0 million, up 2525.76% from the prior year.
• Notes Payables steadied at $260.0 million in Q2 2026 per RSMDF's latest filing, from $259.9 million in the prior quarter.
• Across five years, Notes Payables topped out at $260.0 million in Q2 2026 and bottomed at $9.9 million in Q3 2024.
• Historically, Notes Payables has averaged $65.6 million across 5 years, with a median of $9.9 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Notes Payables dropped 17.5% in 2022, then surged 2526.3% in 2025.
• Over 5 years, Notes Payables stood at $9.9 million in 2022, then slipped by 0.02% to $9.9 million in 2023, then increased by 0.08% to $9.9 million in 2024, then soared by 2523.72% to $259.9 million in 2025, then advanced by 0.02% to $260.0 million in 2026.
• According to Business Quant data, Notes Payables over the past three periods registered $260.0 million, $259.9 million, and $259.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.